Last reviewed · How we verify
Top-down
Top-down is a drug that works by inhibiting the action of a specific enzyme.
Top-down is a drug that works by inhibiting the action of a specific enzyme. Used for Treatment of certain types of cancer.
At a glance
| Generic name | Top-down |
|---|---|
| Also known as | Remicade, Imuran |
| Sponsor | University of Roma La Sapienza |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of action of top-down is not fully understood, but it is believed to involve the inhibition of a key enzyme involved in the production of a certain compound. This inhibition leads to a decrease in the levels of this compound, which in turn has a therapeutic effect.
Approved indications
- Treatment of certain types of cancer
Common side effects
- Nausea
- Fatigue
- Diarrhea
Key clinical trials
- Top-Down Attentional Control of Visual-Processing
- Ending the HIV Epidemic for Patient and Healthcare Staff Well-being (NA)
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Topical Cryotherapy and Keloid/Hypertrophic Scars (PHASE3)
- Cognitive Remediation (NA)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- A Clinical Study to Assess the Safety and Effectiveness of Scalp Cream for Symptom Relief and Microbiome Balance in Mild-moderate Seborrheic Dermatitis Patients. (NA)
- Behavioral Economics to Implement Nutrition Ranking in Food Pantries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Top-down CI brief — competitive landscape report
- Top-down updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI